Key Takeaways GKOS posted Q3 loss of 16 cents per share, beating estimates, with revenue up 38% to $133.5M.GKOS' Glaucoma sales surged 45%, and gross margin rose to 84% from 82% a year ago.GKOS raised 2025 sales outlook to $490-$495M, citing strong iDose TR adoption and FDA-approved Epioxa launch.Glaukos Corporation (GKOS) reported third-quarter 2025 adjusted loss of 16 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 27 cents. The figure also improved from the year-ago qua ...